Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-10, Vol.13 (20), p.5154 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 20 |
| container_start_page | 5154 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Podar, Klaus Leleu, Xavier |
| description | Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies. |
| doi_str_mv | 10.3390/cancers13205154 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534171</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584780636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-d8b119c5a85f9dcead147a46185575e5be2c26f0da94bdb810f273ab10787573</originalsourceid><addsrcrecordid>eNpdkd9LwzAQx4MoTuaefZOCL77U5XdSEEGHv2BDGHsPaZpqR9vUpBX631vdHHN5uBzc577c3ReACwRvCEng1OjaWB8QwZAhRo_AGYYCx5wn9HgvH4FJCGs4PEKQ4OIUjAjlEhJIzsDt0pa6CTabLm3utWmd76NFV7ZFU9po0dvSVToq6ghDDKdDQJGus-jB9q7OzsFJrstgJ9t_DFZPj6vZSzx_e36d3c9jQ6Vo40ymCCWGacnyJDNWZ4gKTTmSjAlmWWqxwTyHmU5omqUSwRwLolMEhRRMkDG428g2XVrZQaBuvS5V44tK-145Xaj_lbr4UO_uS0lGKBJoELjeCnj32dnQqqoIxpalrq3rgsJMUiEhJ3xArw7Qtet8PWz3SxFKkuFyYzDdUMa7ELzNd8MgqH68UQfeDB2X-zvs-D8nyDeZ0IlM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584343980</pqid></control><display><type>article</type><title>Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Podar, Klaus ; Leleu, Xavier</creator><creatorcontrib>Podar, Klaus ; Leleu, Xavier</creatorcontrib><description>Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13205154</identifier><identifier>PMID: 34680303</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Bone marrow ; Bone tumors ; CD38 antigen ; Clinical trials ; COVID-19 ; FDA approval ; Immunosuppressive agents ; Immunotherapy ; Lymphocytes T ; Microenvironments ; Monoclonal antibodies ; Multiple myeloma ; Pandemics ; Pathophysiology ; Patients ; Remission (Medicine) ; Review ; Translation</subject><ispartof>Cancers, 2021-10, Vol.13 (20), p.5154</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-d8b119c5a85f9dcead147a46185575e5be2c26f0da94bdb810f273ab10787573</citedby><cites>FETCH-LOGICAL-c487t-d8b119c5a85f9dcead147a46185575e5be2c26f0da94bdb810f273ab10787573</cites><orcidid>0000-0002-7414-3632</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534171/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534171/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34680303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Podar, Klaus</creatorcontrib><creatorcontrib>Leleu, Xavier</creatorcontrib><title>Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.</description><subject>Bone marrow</subject><subject>Bone tumors</subject><subject>CD38 antigen</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>FDA approval</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Lymphocytes T</subject><subject>Microenvironments</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Pandemics</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Review</subject><subject>Translation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkd9LwzAQx4MoTuaefZOCL77U5XdSEEGHv2BDGHsPaZpqR9vUpBX631vdHHN5uBzc577c3ReACwRvCEng1OjaWB8QwZAhRo_AGYYCx5wn9HgvH4FJCGs4PEKQ4OIUjAjlEhJIzsDt0pa6CTabLm3utWmd76NFV7ZFU9po0dvSVToq6ghDDKdDQJGus-jB9q7OzsFJrstgJ9t_DFZPj6vZSzx_e36d3c9jQ6Vo40ymCCWGacnyJDNWZ4gKTTmSjAlmWWqxwTyHmU5omqUSwRwLolMEhRRMkDG428g2XVrZQaBuvS5V44tK-145Xaj_lbr4UO_uS0lGKBJoELjeCnj32dnQqqoIxpalrq3rgsJMUiEhJ3xArw7Qtet8PWz3SxFKkuFyYzDdUMa7ELzNd8MgqH68UQfeDB2X-zvs-D8nyDeZ0IlM</recordid><startdate>20211014</startdate><enddate>20211014</enddate><creator>Podar, Klaus</creator><creator>Leleu, Xavier</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7414-3632</orcidid></search><sort><creationdate>20211014</creationdate><title>Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond</title><author>Podar, Klaus ; Leleu, Xavier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-d8b119c5a85f9dcead147a46185575e5be2c26f0da94bdb810f273ab10787573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bone marrow</topic><topic>Bone tumors</topic><topic>CD38 antigen</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>FDA approval</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Lymphocytes T</topic><topic>Microenvironments</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Pandemics</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Review</topic><topic>Translation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Podar, Klaus</creatorcontrib><creatorcontrib>Leleu, Xavier</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Biological Sciences</collection><collection>ProQuest Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Podar, Klaus</au><au>Leleu, Xavier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-10-14</date><risdate>2021</risdate><volume>13</volume><issue>20</issue><spage>5154</spage><pages>5154-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34680303</pmid><doi>10.3390/cancers13205154</doi><orcidid>https://orcid.org/0000-0002-7414-3632</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-10, Vol.13 (20), p.5154 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534171 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Bone marrow Bone tumors CD38 antigen Clinical trials COVID-19 FDA approval Immunosuppressive agents Immunotherapy Lymphocytes T Microenvironments Monoclonal antibodies Multiple myeloma Pandemics Pathophysiology Patients Remission (Medicine) Review Translation |
| title | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T15%3A13%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapsed/Refractory%20Multiple%20Myeloma%20in%202020/2021%20and%20Beyond&rft.jtitle=Cancers&rft.au=Podar,%20Klaus&rft.date=2021-10-14&rft.volume=13&rft.issue=20&rft.spage=5154&rft.pages=5154-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13205154&rft_dat=%3Cproquest_pubme%3E2584780636%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584343980&rft_id=info:pmid/34680303&rfr_iscdi=true |